The Cardiometabolic Health Congress (CMHC) is more than an annual conference or regional meeting. Cardiometabolichealth.org provides a single point of access for busy practitioners to stay abreast of evolving science, clinical practice advances and continuing education in cardiometabolic disease prevention and management. CMHC provides a complete platform of education spanning live and digital communications that extends the energy and experience of our national and regional conferences throughout the year and to a wider audience of frontline clinicians with an interest in cardiometabolic health.

The conference will focus on the promising area related to pro-and anti-angiogenic research in human diseases. This conference will bring together researchers and clinicians in this field to foster exchange of ideas and establish collaborations.

EASD 2017 will focus to draw attention towards the topics concerning diabetes and other related subjects. Researches taking place around the globe on clinical and experimental diabetes and metabolism will be discussed.

Dr. Narayanan has a special interest in the genetic basis of neurological disorders. In 2005, he began a clinical research artnership with TGen by establishing the CHC-BNI-TGen Pediatric Neurogenetics Center (Center for Excellence) at the Children’s Health Center, St. Joseph’s Hospital and Medical Center. In 2012 he became the Medical Director for TGen’s Center for Rare Childhood Disorders. The Center uses next generation sequencing to help diagnose children with neurological disorders of unknown genetic etiology.
In the summer of 2014 he moved his research lab to TGen. His research interests include the neurobiology of genetic disorders (genes to pathogenesis), cell adhesion molecules and synapse formation. Current projects deal with Rett syndrome, Tuberous Sclerosis Complex (TSC), Neurofibromatosis 1 (NF1) and other pediatric neurological disorders. He is the director of the Neurofibromatosis Planning Clinic and the Tuberous Sclerosis Clinic at CRS (Children’s Rehabilitative Services)

Seattle is one of the world’s centers of cancer immunotherapy. Three years ago, Xconomy gathered some of the field’s experts to talk about the promises of harnessing the immune system to fight cancer. Today, some of those promises seem well within reach, and a small but growing number of patients are benefiting from a handful of approved (and expensive) drugs. But while the opportunities seem closer at hand, many challenges remain. It’s time to gather again in Seattle to discuss what’s gone right, what’s gone wrong, and how the field’s brightest minds are working through the obstacles inherent when complicated biology, cutting-edge medical practice, and financial pressures meet.